scholarly journals Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study

2021 ◽  
Vol 4 ◽  
pp. 100075
Author(s):  
Andrew Evans ◽  
Victor S.C. Fung ◽  
John D. O'Sullivan ◽  
Rick Stell ◽  
Richard White ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorder ◽  
Cross Sectional ◽  
Advanced Parkinson’S Disease ◽  
The Cross

scholarly journals 026 Characteristics of advanced parkinson’s disease patients seen in movement disorder clinics – australian results from the cross-sectional observe study

2018 ◽  
Vol 89 (6) ◽  
pp. A11.1-A11
Author(s):  
Andrew Evans ◽  
Victor SC Fung ◽  
John O’Sullivan ◽  
Rick Stell ◽  
Richard White ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Movement Disorder ◽  
Brain Stimulation ◽  
Delphi Method ◽  
Cross Sectional ◽  
Advanced Parkinson’S Disease ◽  
Definition Of ◽  
Deep Brain

IntroductionTo evaluate the proportion of Parkinson’s disease (PD) patients identified as having advanced Parkinson’s disease (APD) according to physician’s judgement: Australian results.MethodsThis cross-sectional, non-interventional observational study was performed in movement disorder clinics from 18 countries. Results from the Australian cohort are presented here. Participants included consecutive adults with PD attending a routine clinical visit, or inpatients at participating clinical sites, and who could speak English. The primary outcome was the proportion of patients diagnosed with APD via physician judgement. Secondary objectives included to evaluate clinical characteristics of APD versus non-APD; to assess the percentage of APD considered for device-aided therapies (DAT); to explore referral practices for APD; and to compare the percentage of APD identified in routine clinical practice by physician’s judgment to APD identified based on APD criteria derived using the Delphi method.Results100 patients were recruited in Australia: 61.0% (95%CI 51.4%–70.6%) diagnosed with APD by physician judgement. Patients were 66.6±8.5 years, 65% were male, were living at home (97%), and diagnosed for median 10.7 years (0–30.5 years). Motor fluctuations were present in 68%. For those with APD, referral was predominantly to enable access to DAT (49%), while for non-APD, referral was largely for diagnostic purposes (41%). Referral to a movement disorder clinic occurred 4.8 years (median) following diagnosis for APD, or 3.6 years for non-APD. While 62% were eligible for DAT, only two-thirds of these received them. The most commonly used DAT was deep brain stimulation (64.3%). There was fair agreement between physician’s judgement and the APD criteria by Delphi method (Cohen’s kappa) 0.325 (95%CI 0.150–0.500).ConclusionThe definition of APD requires refinement in order to facilitate greater agreement among movement disorder specialists. A third of PD patients eligible for DAT remain untreated. Current Australian practice is weighted towards deep brain stimulation.

scholarly journals The cross-sectional area of the vagus nerve is not reduced in Parkinson’s Disease patients

2020 ◽  
Author(s):  
Laura C.J. Sijben ◽  
Werner H. Mess ◽  
Uwe Walter ◽  
A. Miranda L. Janssen ◽  
Mark Kuijf ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vagus Nerve ◽  
Cross Sectional Area ◽  
List Type ◽  
Sectional Area ◽  
Cross Sectional ◽  
Autonomic Symptoms ◽  
The Cross ◽  
The Right

AbstractObjectiveRecent studies have revealed the importance of the gut brain axis in the development of Parkinson’s disease (PD). It has also been suggested that the cross-sectional area (CSA) of the vagus nerve can be used in the diagnosis of PD. Here, we hypothesize that the CSA of the vagus nerve is decreased in PD patients compared to control subjects.MethodsIn this study we measured the CSA of the vagus nerve on both sides in 31 patients with PD and 51 healthy controls at the level of the common carotid artery using high-resolution ultrasound.ResultsThe CSA of the vagus nerve was not reduced in PD patients compared to controls (p = 0.391. The mean CSA of the left vagus nerve was significantly smaller than the right (p < 0.001). There was no significant correlation between age, gender and autonomic symptoms with the CSA of the left (p = 0.128) and right vagus nerve (p = 0.166).ConclusionThese findings show that the CSA of the vagus nerve using ultrasonography is not a reliable diagnostic tool in the diagnosis of PD.HighlightsThe cross-sectional area of the vagus nerve is not decreased in Parkinson disease patients.The cross-sectional area of the vagus nerve does not correlate with autonomic symptoms.Measurement of the vagus nerve cross-sectional area has a high inter-observer correlation.

scholarly journals DOPA-sparing strategy in the treatment of young onset Parkinson’s disease

2016 ◽  
Vol 7 (01) ◽  
pp. 67-69 ◽  
Author(s):  
Abdul Qayyum Rana ◽  
Mohamad Saleh ◽  
Muhammad Saad Yousuf ◽  
Wasim Mansoor ◽  
Syed Hussaini ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorder ◽  
Neurodegenerative Disorder ◽  
Late Onset ◽  
Retrospective Chart Review ◽  
Cross Sectional Study ◽  
Community Based ◽  
Cross Sectional ◽  
Young Onset

ABSTRACT Context: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the trend in the choice of drug administered to patients with both YOPD and LOPD, with particular emphasis on this trend in its relation to the practice background of the neurologist. Settings and Design: A cross-sectional study was conducted in a community based Parkinson’s disease and movement disorder clinic. Statistical Analysis Used: Using a retrospective chart review data was obtained and analysed. Results: The results showed that 83% of general neurologists prescribed levodopa to their patients with YOPD, whereas movement-disorder specialists took a different approach altogether. They opted not to use levodopa and, in its stead, prescribed a mixture of alternate drugs.

scholarly journals Prevalence and profile of nocturnal disturbances in Chinese patients with advanced-stage Parkinson’s disease: a cross-sectional epidemiology study

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Guiying He ◽  
Chun-Feng Liu ◽  
Qinyong Ye ◽  
Zhenguo Liu ◽  
Miao Jin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Care Hospital ◽  
Cross Sectional ◽  
Advanced Parkinson’S Disease ◽  
Female Sex ◽  
The Impact ◽  
Off Time

Abstract Background The impact of nocturnal disturbance (ND) in Parkinson’s disease on quality of life of patients in Western Countries is increasingly understood. Our study aimed to investigate ND prevalence and its quality of life impact in patients with advanced Parkinson’s disease in China. Methods In a multicenter, tertiary-care hospital, outpatient-based, cross-sectional study, patients with advanced Parkinson’s disease (Modified Hoehn & Yahr [H&Y] Stage II–IV with ≥3 h awake “off” time/day) from 10 tertiary hospitals throughout China completed the Parkinson’s Disease Sleep Scale-2 (PDSS-2) and Parkinson’s Disease Questionnaire-39 (PDQ-39). The primary endpoint was the percentage of patients with significant ND (PDSS-2 total score ≥ 15). Additional endpoints were demographic and clinical characteristics, PDSS-2 and PDQ-39 total and subscale scores, correlation between PDSS-2 and PDQ-39, and risk factors for ND and higher PDSS-2 or PDQ-39 scores. Results Of 448 patients analyzed (mean age 63.5 years, 47.3% female), 70.92% (95% confidence interval: 66.71, 75.13) had significant ND. Presence of ND and higher PDSS-2 scores were associated with longer disease duration and higher H&Y stage. Presence of ND was also associated with more awake “off” time/day and female sex. PDQ-39 scores were significantly worse for patients with ND versus those without ND; worse scores were associated with more awake “off” time/day, female sex, and higher H&Y stage. PDSS-2 and PDQ-39 total scores were associated: Pearson correlation coefficient 0.62 (p < 0.001). Conclusions In China, ND was highly prevalent in patients with advanced Parkinson’s disease and adversely impacted quality of life. This study highlights the importance of early diagnosis and optimized management of ND in patients with Parkinson’s disease in China.

Chronic pain in Parkinson's disease: The cross-sectional French DoPaMiP survey

2008 ◽  
Vol 23 (10) ◽  
pp. 1361-1369 ◽  
Author(s):  
Laurence Nègre-Pagès ◽  
Wafa Regragui ◽  
Didier Bouhassira ◽  
Héléne Grandjean ◽  
Olivier Rascol ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Chronic Pain ◽  
Parkinson's Disease ◽  
Cross Sectional ◽  
The Cross

306 CHRONIC PAIN IN PARKINSON'S DISEASE: THE CROSS-SECTIONAL DOPAMIP SURVEY

2007 ◽  
Vol 11 (S1) ◽  
pp. S135-S136
Author(s):  
O. Rascol ◽  
L. Negre-Pages ◽  
D.S.G. Dopamip ◽  
Keyword(s):  
Parkinson’S Disease ◽  
Chronic Pain ◽  
Parkinson's Disease ◽  
Cross Sectional ◽  
The Cross

scholarly journals Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis

2021 ◽  
Vol 11 (12) ◽  
pp. 1566
Author(s):  
Mihaela Adriana Simu ◽  
Dragos Catalin Jianu ◽  
Adriana Octaviana Dulamea ◽  
Viorelia Adelina Constantin ◽  
Diana Popescu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Long Term Outcomes ◽  
Disease Treatment ◽  
Cross Sectional ◽  
Advanced Parkinson’S Disease ◽  
Retrospective Data Collection ◽  
The Moment ◽  
Treatment Simplification

The aim of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS) was to assess the use of levodopa/carbidopa intestinal gel (LCIG) as monotherapy in patients with advanced Parkinson’s disease (APD) in routine clinical practice. COSMOS was an international observational study with one cross-sectional visit and retrospective data collection. In Romania, 95 adult patients with APD on LCIG treatment for at least 12 months were enrolled and stratified according to their LCIG therapy after 12 months: monotherapy (without any add-on PD medication), monotherapy with night PD medication and LCIG + add-on medication. Compared to the moment of LCIG initiation, the percentage of patients on monotherapy increased at three months after LCIG initiation and remained constant up to 12 months, when 30.5% of the patients were on LCIG monotherapy and 11.6% were on monotherapy with night medication. “Off” time and “On” time with dyskinesia decreased from LCIG initiation to patient visit in all groups. LCIG monotherapy with or without night medication may provide a simplified treatment option for selected APD patients, with long-term efficacy similar to that of LCIG plus add-on medication.

scholarly journals Characterizing Advanced Parkinson’s Disease: Romanian Subanalysis from the OBSERVE-PD Study

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Jozsef Attila Szasz ◽  
Dragos Catalin Jianu ◽  
Mihaela Adriana Simu ◽  
Viorelia Adelina Constantin ◽  
Adriana Octaviana Dulamea ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Judgement ◽  
Patient Acceptance ◽  
Cross Sectional ◽  
Advanced Parkinson’S Disease ◽  
Treatment Complications ◽  
Appropriate Treatment ◽  
Clinical Tools

OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disorders Centers (MDCs) in 18 countries. Overall, the study enrolled 2615 patients. The aim was to determine the proportion of patients with advanced Parkinson’s disease (APD) versus non-APD from MDCs and to uncover the clinical burden of APD, as well as a correlation between overall assessment of APD and several indicators of APD. The advanced stage of the disease and severity were assessed by investigators using their clinical judgement. Data were collected during a single visit between February 2015 and January 2016. Agreement on physician judgement of APD diagnosis and fulfillment of at least one previously established APD indicator was calculated. Motor and nonmotor symptoms (NMSs), activities of daily living, treatment complications, quality of life (QoL), conventional treatments, and device-aided therapy (DAT) eligibility were assessed. Here, country-specific results of 161 Romanian patients with PD are presented. In total, 59.0% of patients were diagnosed with APD and 78.8% met at least one APD indicator. There was only moderate agreement between clinical judgement of APD and overall fulfillment of APD indicators. All scores related to motor symptoms, NMSs, and treatment complications, as well as to QoL, showed a higher disease burden for patients with APD versus non-APD. Physicians considered 73.7% of patients with APD eligible for DAT. The majority of patients eligible for DAT (54.3%) did not receive such treatment. Our results highlight the importance of earlier recognition of APD, by combining clinical judgement with more standardized clinical tools, such as generally recognized APD criteria. However, timely diagnosis of APD alone is not enough to improve patient outcomes. Other critical factors include patient acceptance and access to appropriate treatment.

Sign in / Sign up

Export Citation Format

Share Document